Cardiff Oncology Sees Unusually High Options Volume (NASDAQ:CRDF)

Cardiff Oncology, Inc. (NASDAQ:CRDF) was the target of some unusual options trading activity on Tuesday. Stock investors purchased 2,705 call options on the company. This is an increase of 288% compared to the average volume of 698 call options.

Wall Street Analyst Weigh In

CRDF has been the topic of several research analyst reports. Noble Financial started coverage on shares of Cardiff Oncology in a research report on Monday, January 5th. They set an “outperform” rating and a $12.00 price target on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cardiff Oncology in a research report on Wednesday, January 21st. Four equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Cardiff Oncology has an average rating of “Moderate Buy” and a consensus target price of $11.13.

Institutional Investors Weigh In On Cardiff Oncology

Institutional investors have recently made changes to their positions in the company. Blair William & Co. IL increased its position in shares of Cardiff Oncology by 44.1% in the 2nd quarter. Blair William & Co. IL now owns 2,524,118 shares of the company’s stock valued at $7,951,000 after acquiring an additional 772,844 shares during the period. Laurion Capital Management LP lifted its position in Cardiff Oncology by 37.2% during the 3rd quarter. Laurion Capital Management LP now owns 2,465,872 shares of the company’s stock worth $5,080,000 after acquiring an additional 668,590 shares during the period. Acorn Capital Advisors LLC grew its stake in Cardiff Oncology by 39.3% during the 3rd quarter. Acorn Capital Advisors LLC now owns 1,962,084 shares of the company’s stock valued at $4,042,000 after purchasing an additional 553,317 shares during the last quarter. Geode Capital Management LLC increased its holdings in shares of Cardiff Oncology by 7.5% in the second quarter. Geode Capital Management LLC now owns 1,498,838 shares of the company’s stock valued at $4,723,000 after purchasing an additional 104,409 shares during the period. Finally, Flputnam Investment Management Co. raised its stake in shares of Cardiff Oncology by 1,008.8% in the third quarter. Flputnam Investment Management Co. now owns 597,233 shares of the company’s stock worth $1,230,000 after purchasing an additional 543,370 shares during the last quarter. Institutional investors own 16.29% of the company’s stock.

Cardiff Oncology Stock Down 34.4%

CRDF traded down $1.01 during trading on Tuesday, hitting $1.93. The company’s stock had a trading volume of 6,047,238 shares, compared to its average volume of 1,045,943. The firm has a market cap of $129.94 million, a PE ratio of -2.44 and a beta of 1.40. The business’s 50 day simple moving average is $2.61 and its 200-day simple moving average is $2.53. Cardiff Oncology has a one year low of $1.85 and a one year high of $4.99.

Cardiff Oncology (NASDAQ:CRDF) last posted its quarterly earnings results on Thursday, November 6th. The company reported ($0.17) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.03. The business had revenue of $0.12 million during the quarter, compared to analyst estimates of $0.12 million. Cardiff Oncology had a negative net margin of 10,064.27% and a negative return on equity of 77.21%. Equities research analysts expect that Cardiff Oncology will post -0.99 EPS for the current fiscal year.

About Cardiff Oncology

Cardiff Oncology, Inc is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts. The company is dedicated to the discovery, development and commercialization of novel small-molecule therapies designed to modulate the tumor microenvironment and enhance antitumor immune responses. By focusing on unique immuno-oncology targets, Cardiff seeks to address resistance pathways that limit the effectiveness of existing cancer treatments.

Cardiff’s pipeline comprises several small-molecule immunomodulators in various stages of preclinical and clinical development.